#United States #Menlo Park #Mayo Clinic #MyOme #Preventative Care

MyOme Teams Up with Mayo Clinic to Innovate Preventative Healthcare

In a significant advancement for the healthcare sector, MyOme, Inc. has joined the Mayo Clinic Platform_Accelerate cohort. This initiative is set to revolutionize preventative healthcare by utilizing artificial intelligence (AI) and extensive, de-identified clinical datasets. As a leader in whole-genomic analysis and polygenic risk scores, MyOme is now positioned to enhance its cutting-edge Integrated Risk Models (IRMs).

A Leap Towards Proactive Care

The partnership with Mayo Clinic aims to shift the focus of healthcare from a reactive to a proactive approach. MyOme’s innovative technology integrates whole-genome sequencing and clinical data analysis to identify individuals at a higher risk for common health issues, such as cardiometabolic diseases and various cancers. By harnessing the power of AI, MyOme aspires to surface risk factors well before any diseases manifest, allowing for timely interventions that could prevent or delay health complications.

Leveraging Extensive Clinical Data

As part of their collaboration, MyOme will gain access to a vast, five-year de-identified dataset of approximately three million patients. This invaluable resource will enable MyOme to validate and enhance the performance of its IRMs across more than 20 health conditions, both rare and common. With the integration of deep-learning techniques, MyOme aims to significantly improve the accuracy and efficiency of risk predictions, ultimately leading to healthier, longer lives for patients.

Dr. Akash Kumar, Chief Medical and Science Officer at MyOme, emphasized the importance of this partnership. He stated, "Access to high-quality clinical data through Mayo Clinic is a game-changer for us. It allows us to refine our next-generation integrated risk models that combine detailed medical histories with genomic information. Our mission is straightforward—achieving more accurate risk assessments and targeted interventions."

Driving Equitable Healthcare

The collaboration also aims to generate evidence that supports reimbursement pathways to enhance equitable access to genomics-based screenings. By demonstrating the effectiveness of their advanced risk models, MyOme hopes to ensure that more individuals benefit from cutting-edge genomic insights into their health.

MyOme's Commitment to Innovation

Founded in Menlo Park, California, MyOme operates a CLIA-certified and CAP-accredited laboratory. It offers comprehensive clinical workflows designed for healthcare practitioners and their patients. Its Proactive Health Report encompasses a range of crucial analyses, including single-gene risk assessments and medication response reports alongside various IRMs. Furthermore, in March 2025, MyOme rolled out its inaugural whole-genome-based diagnostic test aimed at identifying rare diseases.

This partnership signals a pivotal moment in preventive health, potentially reshaping how risks are assessed and managed. By combining cutting-edge AI tools with extensive clinical data, MyOme and Mayo Clinic are setting a new standard in genomic healthcare that may change countless lives for the better.

For further insights about Mayo Clinic Platform_Accelerate, visit their official page. To learn more about MyOme, check out MyOme's website.